Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Resectable Biliary Tract Cancers
NCT06001658Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in biliary tract cancer (BTC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06001658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001658.